logo-loader
Callitas Health Inc.

Callitas Health appoints former interim CEO as M&A consultant

Keane is currently CEO of Qualified Capital Consultants and co-founder of 420 Acquisitions LLC

handshake
The Cincinnati-based company develops technologies for weight management, female sexual health and wellness and cannabis delivery

Callitas Health Inc (CSE:LILY) (OTCMKTS:MPHMF) (FWB:T3F3), the clinical-stage pharmaceutical company, named former interim CEO Brian Keane capital markets and merger and acquisitions consultant.

Keane is currently CEO of Qualified Capital Consultants and co-founder of 420 Acquisitions LLC. He also served as founding director at 1933 Industries Inc (CSE:TGIF) (OTCMKTS:TGIFF).

He also brings a wealth of M&A experience from his time at Deutsche Bank (NYSE:DB), Rodman and Renshaw, Ladenburg Thalmann & Co, Techvest LLC and Yorkville Advisors.

READ: Callitas Health wins notice of allowance from US Patent and Trademark Office in regards to patent for new cannabis 'candy'

"We are proud to welcome Brian back to the Callitas team,” CEO James Thompson said. “As prior interim CEO, Brian is familiar with our patented delivery technology, as well as the multiple assets that are owned by the company that will be evaluated for monetization as we expand into the legal cannabis market.”

Callitas is a Cincinnati-based company focused on developing technologies to address weight management, female sexual health and wellness, and cannabis delivery.

Shares were unchanged on the CSE at C$10 and at $US0.09 on OTC markets.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Callitas Health Inc.

Price: $0.11

Market: CSE
Market Cap: $3.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc. named herein, including the promotion by the Company of Callitas Health Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Callitas Therapeutics signs LOI with Simply Wholeistic, updates on THC & CBD...

Callitas Therapeutics (CSE:LILY) (OTCQB:MPHMF) Vice President of Sales & Business Development Joshua Maurice tells Proactive Investors the pharma company has signed a letter of intent with Simply Wholeistic to manufacture  its CannaStrip products in the U.S. Maurice added that as...

on 04/25/2019

2 min read